Antitumor activity of bis-indole derivatives.

This paper reports the synthesis of compounds formed by two indole systems separated by a heterocycle (pyridine or piperazine). As a primary screening, the new compounds were submitted to the National Cancer Institute for evaluation of antitumor activity in the human cell line screen. The pyridine derivatives were far more active than the piperazine derivatives. For the study of the mechanism of action, the most active compounds were subjected to COMPARE analysis and to further biological tests including proteasome inhibition and inhibition of plasma membrane electron transport. The compound bearing the 5-methoxy-2-indolinone moiety was subjected to the first in vivo experiment (hollow fiber assay) and was active. It was therefore selected for the second in vivo experiment (human tumor xenograft in mice). In conclusion we demonstrated that this approach was successful, since some of the compounds described are much more active than the numerous, so far prepared and tested 3-indolylmethylene-2-indolinones.

[1]  R. Shoemaker,et al.  New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. , 2008, Journal of medicinal chemistry.

[2]  M. Berridge,et al.  The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. , 2007, Biochemical pharmacology.

[3]  N. Calonghi,et al.  Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis. , 2007, Journal of medicinal chemistry.

[4]  M. Berridge,et al.  Plasma membrane electron transport: a new target for cancer drug development. , 2006, Current molecular medicine.

[5]  A. Seth,et al.  Novel RING E3 ubiquitin ligases in breast cancer. , 2006, Neoplasia.

[6]  Yili Yang,et al.  A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. , 2005, Cancer research.

[7]  A. Seth,et al.  Molecular Characterization of Ring Finger Protein 11 , 2005, Molecular Cancer Research.

[8]  S. Doggrell.  RITA - a small-molecule anticancer drug that targets p53 , 2005, Expert opinion on investigational drugs.

[9]  L. Masotti,et al.  Substituted E-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. , 2004, Bioorganic & medicinal chemistry.

[10]  A. Zakrzewska,et al.  4‐Fluoroanilines: Synthesis and Decomposition. , 2002 .

[11]  A. Andreani,et al.  Synthesis and Antitumor Activity of 1,5,6-Substituted E-3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones1 , 2002 .

[12]  M. Kiniwa,et al.  Synthesis of a magnosalin derivative, 4-(3,4,5-trimethoxyphenyl)-6-(2,4,5-trimethoxyphenyl)-2-diethylaminopyrimidine, and the anti-angiogenic and anti-rheumatic effect on mice by oral administration. , 2002, Bioorganic & medicinal chemistry letters.

[13]  H. Fiebig,et al.  Human Tumor Xenografts: Predictivity, Characterization and Discovery of New Anticancer Agents , 1999 .

[14]  H. Fiebig,et al.  Human Tumor Cell Lines Demonstrating the Characteristics of Patient Tumors as Useful Models for Anticancer Drug Screening , 1999 .

[15]  A. Andreani,et al.  Synthesis and potential coanthracyclinic activity of pyridylmethylene and indolylmethylene lactams , 1998 .

[16]  A. Andreani,et al.  Potential coanthracyclinic activity of pyridylmethylene-2-indolinones. , 1998, Anticancer research.

[17]  G. Mcmahon,et al.  Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. , 1998, Journal of medicinal chemistry.

[18]  S. Fustinoni,et al.  Synthesis and Configuration of Some New Bicyclic 3-Arylidene- and 3- Heteroarylidene-2-oxindoles. , 1995 .

[19]  R. Mertelsmann,et al.  Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. , 1995, Anti-cancer drugs.

[20]  M R Grever,et al.  In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.

[21]  K D Paull,et al.  Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. , 1992, Cancer research.

[22]  H. Fiebig,et al.  Combined in vitro/in vivo test procedure with human tumor xenografts for anticancer drug development. , 1992, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[23]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[24]  A. Andreani,et al.  Synthesis and cardiotonic activity of 2-indolinones , 1990 .

[25]  H. Ogawa,et al.  Studies on positive inotropic agents. V. Synthesis of 1-heteroaroylpiperazine derivatives. , 1988, Chemical & pharmaceutical bulletin.

[26]  A. Katritzky,et al.  Conjugated systems derived from piperazine‐2,5‐dione , 1988 .

[27]  D. Mizuno,et al.  ANTITUMOR ACTIVITY OF INDOLE DERIVATIVES , 1978 .

[28]  H. V. Dobeneck,et al.  Zur Chemie des Indols, VI. α.β′‐Diindolylmethane und ‐methene. Der Urorosein‐Chromophor , 1969 .

[29]  A. Andreani,et al.  Synthesis and antitumor activity of 1,5,6-substituted E-3-(2-chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones. , 2002, Journal of medicinal chemistry.

[30]  Melinda G. Hollingshead,et al.  Human Tumor Xenograft Models in NCI Drug Development , 1997 .

[31]  A. Andreani,et al.  Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups , 1993 .

[32]  R. Robinson,et al.  112. Monothiophthalimide and some derivatives of oxindole , 1941 .